Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study
Authors:
- Julia E.C. Van SteenhovenJSJulia E.C. Van Steenhoven
- Anne KuijerAKAnne Kuijer
- Paul J. Van DiestPDPaul J. Van Diest
- Joost M. Van GorpJGJoost M. Van Gorp
- Marieke StraverMSMarieke Straver
- Sjoerd G. EliasSESjoerd G. Elias
- Jelle WesselingJWJelle Wesseling
- Emiel RutgersEREmiel Rutgers
- Johanna N.H. Timmer-BonteJTJohanna N.H. Timmer-Bonte
- Peter NieboerPNPeter Nieboer
- Tineke J. SmildeTineke J. Smilde
- Alex ImholzAIAlex Imholz
Open Access
Abstract
In this study, in estrogen receptor positive (ER+) early stage breast cancer patients who were considered candidates for 70-gene signature (70-GS, “MammaPrint”) use, we compared molecular subtyping (MS) based on the previously validated 80-gene signature (80-GS, “BluePrint”) versus surrogate pathological subtyping (PS). Between 1 January 2013 and 31 December 2015, 595 clinical intermediate risk ER+ early stage breast cancer patients were enrolled. Hormone receptor (HR) and HER2 receptor status were determined by conventional pathology using immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH). Ki67 was assessed in a subset of patients. The overall concordance between PS and MS for luminal type cancers (A and B together) was 98%. The concordance between PS and MS for luminal A and luminal B type cancers based on the Bloom Richardson histological grade (BR) (n = 586) or Ki67 (n = 185) was low: 64% (Kappa 0.20 [95% CI 0.11–0.28]) and 65% (Kappa 0.22 [95% CI 0.062–0.37]), respectively. In this prospective study (NCT02209857) of a selection of ER+ and predominantly HER2− early-stage breast cancer patients, the additional ability of the 80-GS to distinguish between luminal, HER2-type and basal-like cancers was inherently very limited. The distinction of luminal-type tumors into A and B according to Ki67 status or BR grade versus the 70-GS revealed poor concordance.Keywords
This publication has 35 references indexed in Scilit:
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast CancerNew England Journal of Medicine, 2016
- Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 UpdateArchives of Pathology & Laboratory Medicine, 2016
- Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)Annals of Surgical Oncology, 2014
- Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapyBreast Cancer Research and Treatment, 2013
- A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast CancerClinical Cancer Research, 2010
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- Molecular portraits of human breast tumoursNature, 2000